文献速递肺外科

重视中叶:双肺叶切除与肺叶切除及全肺切除的围手术期风险比较

Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy.
PubMed 文献 · Ann Thorac Surg · 2023-09-27

基于美国胸外科医师学会数据库2009至2017年数据,回顾性分析2911例双肺叶切除、65506例肺叶切除和3370例全肺切除患者。倾向性匹配后,双肺叶切除30天死亡率与左全肺切除相当(HR 1.35,95%CI 0.95-1.91,P=0.09),显著劣于左肺叶切除(HR 0.40,95%CI 0.29-0.56,P<0.0001)和右肺叶切除(HR 0.43,95%CI 0.31-0.59,P<0.0001),但较右全肺切除有生存优势(HR 2.54,95%CI 1.72-3.74,P<0.0001)。

要点

  • 双肺叶切除30天死亡率与左全肺切除相当,显著高于左或右肺叶切除。
  • 双肺叶切除30天并发症高于肺叶切除,上双肺叶切除30天死亡率优于下双肺叶切除。
  • 双肺叶切除较右全肺切除有生存优势,但风险仍不容忽视,术前风险分层需仔细考虑。

核心结论

  • 双肺叶切除的并发症和死亡率显著劣于肺叶切除,与左全肺切除相当。
  • 在肺切除基础上增加中叶切除并非没有风险,术前风险分层时应仔细考虑。

研究设计与样本

  • 回顾性分析美国胸外科医师学会数据库2009至2017年因肺癌行肺叶切除、双肺叶切除或全肺切除的患者。
  • 主要结局为30天围手术期死亡率,按患者人口学、合并症和围手术期变量对每种手术类型与双肺叶切除进行倾向性匹配,并运行Cox比例风险模型。
  • 次要结局比较上双肺叶切除与下双肺叶切除的30天并发症和死亡率。

主要发现

  • 研究期间共2911例双肺叶切除、65506例肺叶切除和3370例全肺切除患者符合纳入标准。
  • 行全肺切除和双肺叶切除的患者合并症少于肺叶切除患者。
  • 倾向性匹配后,双肺叶切除30天死亡率与左全肺切除相当(HR 1.35,95%CI 0.95-1.91,P=0.09)。
  • 双肺叶切除30天死亡率显著劣于左肺叶切除(HR 0.40,95%CI 0.29-0.56,P<0.0001)和右肺叶切除(HR 0.43,95%CI 0.31-0.59,P<0.0001)。
  • 双肺叶切除较右全肺切除有生存优势(HR 2.54,95%CI 1.72-3.74,P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In some cases of right-sided lung cancer, tumor extension, bronchial involvement, or pulmonary artery infiltration may necessitate bilobectomy. Although the middle lobe is believed to represent a fraction of total lung function, the morbidity and mortality associated with bilobectomy is not well described. METHODS: We retrospectively identified patients in The Society of Thoracic Surgeons Database who underwent lobectomy, bilobectomy, or pneumonectomy for lung cancer from 2009 to 2017. The primary outcome was 30-day perioperative mortality. We performed propensity matching by patient demographics, comorbidities, and perioperative variables for each surgical type against bilobectomy and ran Cox proportional hazard models. Secondary outcomes of 30-day morbidity and mortality of upper vs lower bilobectomy were also compared. RESULTS: Within the study period 2911 bilobectomy, 65,506 lobectomy, and 3370 pneumonectomy patients met the inclusion criteria. Patients undergoing pneumonectomy and bilobectomy had fewer comorbidities than lobectomy patients. After propensity matching 30-day mortality of bilobectomy was comparable with left pneumonectomy (hazard ratio [HR], 1.35; 95% CI, 0.95-1.91; P = .09) and significantly worse than left (HR, 0.40; 95% CI, 0.29-0.56; P < .0001) or right (HR, 0.43; 95% CI, 0.31-0.59; P < .0001) lobectomy. Bilobectomy was associated with a survival advantage compared with right pneumonectomy (HR, 2.54; 95% CI, 1.72-3.74; P < .0001). Thirty-day morbidity was higher for bilobectomy compared with lobectomy, and upper bilobectomy had a significant unadjusted 30-day mortality advantage compared with lower bilobectomy (98.3% vs 97%, P = .04). CONCLUSIONS: The morbidity and mortality of bilobectomy is significantly worse than lobectomy and is comparable with left pneumonectomy. The addition of middle lobectomy to a pulmonary resection is not without risk and should be carefully considered during preoperative risk stratification.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Li AX, Canavan ME, Ermer T, et al. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. Ann Thorac Surg. 2023. PMID: 37774762. doi:10.1016/j.athoracsur.2023.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。